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1 Abstract
Recently, the variability ratio (VR) effect size statis-
tic has been used with increasing frequency in the
study of differences in variation of a measured vari-
able between two study populations. More specifically,
the VR effect size statistic allows for the detection
of treatment effect heterogeneity (TEH) of medical
interventions. While a VR that is different from 1 is
widely acknowledged to implicate a treatment effect
heterogeneity (TEH) the exact relationship between
those two quantities has not been discussed in detail
thus far.
In this note we derive a precise connection between
TEH and VR. In particular, we derive precise upper
and lower bounds on the TEH in terms of VR. More-
over, we provide an exemplary simulation for which
VR is equal to 1 and there exist TEH.
Our result has implications for the interpretation of
VR effect size estimates regarding its connection to
treatment effect heterogeneity of (medical) interven-
tions.
Keywords — variability ratio, treatment effect het-
erogeneity, causal inference
2 Introduction
Recently, the variability ratio (VR) effect size statistic
(defined in Hedges and Nowell (1995), and proposed
in Nakagawa et al. (2015)) has been used in various
meta-analyses to investigate the difference of the total
amount of variance present between two experimental
groups.
Senior et al. (2016) compared the effects of two dietary
interventions on variability in weight. Winkelbeiner et
al. (2019), McCutcheon et al. (2019) and Mizuno et
al. (2020) studied the variability of antipsychotic drug
∗Marienburger Str. 21, 10405 Berlin, alexv@gmx.de
0Abbreviations: VR, variability ratio; TEH, treatment
effect heterogeneity
response in schizophrenia. Plöderl and Hengartner
(2019), Maslej et al. (2020) and Volkmann, Volk-
mann, and Mueller (2020) investigated the variability
of antidepressants’ response in depression.
Other recent works that have used the VR effect
size statistic in order to compare the variability be-
tween two groups include Brugger and Howes (2017),
Pillinger et al. (2019), Rogdaki et al. (2020) as well
as Brugger et al. (2020).
While a VR that is different from 1 is widely acknowl-
edged to implicate a variation in treatment effect the
exact relationship between those two quantities has
not discussed in detail thus far.
The purpose of this note is to derive a precise con-
nection between the TEH and the VR. Moreover, we
provide an exemplary simulation for which VR is equal
to 1, yet there exist substantial TEH.
3 Methods – Individual treat-
ment effect
The treatment effect of individual i with respect to a
given (medical) treatment is defined as (cf. e.g. Mor-
gan and Winship (2015)),
δi = Y 1i − Y 0i ,
where Y ai denotes the potential outcome of individual
i with respect to treatment a ∈ {0, 1}. The potential
outcome Y ai represents the outcome that the individ-
ual i would have had, had the individual i received
the treatment a, irrespective of the factual treatment,
the treatment that actually was received by the indi-
vidual. The fundamental problem of causal inference
(see Holland (1986)), states that we can never observe
both Y 1i and Y 0i at the same time. Moreover, the no-
tation reflects the fact that we make the Stable Unit
Treatment Value Assumption (SUTVA) assumption,
which allows us to write the potential outcomes for
an individual i as a function of the individual’s own
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treatment assignment alone, rather than the treat-
ment assignment of all individuals in the population.
Mathematically, Y a1,...,ai,...i ≡ Y aii . This assumption
is not always valid. In case the treatment refers to
a vaccination against a disease the assumptions is
violated, since the effect of a potential vaccination of
an individual i depends on whether others have been
vaccinated.
In the following we consider the so-called super-
population perspective, in which we view our sample
Y 0i , Y
1
i of size N as a random sample from an infi-
nite population. More formally, we consider Y ai to
be realizations of a population level random variable
Y a. Similarly, δi are realizations of a population level
random variable δ.
In summary, there are two levels of randomness that
we consider. Firstly, we randomly draw individuals
i = 1, ..., N from an infinite population, each indi-
vidual having an associated pair (Y 0i , Y 1i ) of poten-
tial outcomes. Secondly, a predetermined number
(0 < N1 < N) of individuals get randomly assigned
to treatment (a = 1), the remaining (N0 = N −N1)
individuals get assigned to the control (a = 0) group,
and the associated outcomes Yi = Y ai are observed.
The uncertainty in any type of estimate that results
from these two levels of randomness may be referred
to as sampling-based and design-based uncertainty,
respectively (see Abadie et al. (2020)).
Notably, there is an additional layer of randomness
that might be considered. We could assume that for
each individual i, Y ai are random variables rather than
mere realizations of a population level random variable
Y a. In this case one might refer to δi as the random
treatment effect of the individual i. Realizations yai
of Y ai could be viewed as draws from a “metaphorical
population, comprising the possible eventualities that
might have occurred but mainly didn’t” (see Spiegel-
halter (2019)). Alternatively, the source for this part
of the randomness could be a model for measurement
error, epistemological uncertainty, or could reflect the
assumption that the individual i has a truly random
outcome.
3.1 Treatment effect heterogeneity
Treatment effect heterogeneity (TEH) is present if
not all individuals have the same individual treatment
effect, i.e. δi is not the same for all individuals. In
the language of the super-population perspective this
means that V ar(δ) > 0. Of course, in any practical
situation it is impossible not to have TEH. The more
interesting question to study is the question about
the degree or the magnitude of TEH. It can be quan-
tified by estimating the magnitude of V ar(δ) or by
identifying a relevant (w.r.t. the application at hand)
subgroup X of the population for which E[δ|X]−E[δ]
is large.
In the case of random individual treatment effect, we
need to distinguish between inter- and intra-individual
TEH. The inter-individual TEH could be defined as
the variation between individuals of the average ran-
dom individual treatment effect (E[δi]).
3.2 Variability Ratio
We define the variability ratio ν (cf. Hedges and Nowell
(1995)) as
ν = σ1
σ0
,
where σ2a = V ar(Y a), for a = 0, 1, are the super-
population variances.
In the case of sufficiently large sample sizes N0, N1,
sufficiently large values σa and (approximately) nor-
mally distributed ln σa, an unbiased estimator of ln ν
and its sample variance (cf. Raudenbush and Bryk
(1987); Nakagawa et al. (2015)) are given by
lnV R = ln
(
s1
s0
)
+ 12(N1 − 1) −
1
2(N0 − 1)
s2lnV R =
1
2(N1 − 1) −
1
2(N0 − 1) .
Here, s0 and s1 denote the finite sample variances of
treatment and control units’ observed scores Yi.
4 Results – Treatment effect
heterogeneity and variability
ratio
In order to derive the main analytical relationship
between TEH and the VR effect size statistic we
consider two time points t = 0 (baseline) and t = 1
(endpoint). We denote by Y ait the potential outcomes
of individual i at time t with respect to the treatment
a. We assume that Y 0i0 ≡ Y 1i0, i.e. there is no effect at
baseline. Then, we may write
Y ai1 = Y ai0 + (Y 0i1 − Y ai0) + a · (Y 1i1 − Y 0i1)
= Y 0i0 + (Y 0i1 − Y 0i0) + a · (Y 1i1 − Y 0i1)
=def αi + τi + a · δi.
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In words, this means that we can decompose the
potential outcome score Y ai1 of individual i at endpoint
(t = 1) under treatment a as the sum of the following
quantities (Figure 1):
• the baseline score (aka the pre-treatment score)
of individual i
• the temporal change of score (aka the response)
of individual i under control
• the treatment effect of individual i in case a = 1
and zero otherwise.
Figure 1: Decomposition of the potential outcomes
Y a1 .
We then have for the difference in variance in temporal
change
V ar(Y 11 − Y 10 )− V ar(Y 01 − Y 00 )
= V ar(δ) + 2Cov(τ, δ)
= V ar(δ) + 2ρ V ar(τ) 12V ar(δ) 12 . (1)
Here, ρ denotes the correlation between τ , the change
(or response) score under control, and δ, the treatment
effect. Note that this quantity is not observable since
it contains information about the correlation between
both potential outcomes Y 01 and Y 11 .
4.1 Compatible values of TEH and
VR
With equation (1) at hand, we are ready to derive
restrictions on the standard deviation σδ = V ar(δ)
1
2
of the treatment effect δ.
Let ν be the variability ratio defined with respect to
the response variables Y a = Y a1 − Y a0 . Then, we have
that
ν2 − 1 = V ar(Y
1
1 − Y 10 )− V ar(Y 01 − Y 00 )
V ar(Y 01 − Y 00 )
= V ar(δ) + 2ρ V ar(τ)
1
2V ar(δ) 12
V ar(τ)
= σ
2
δ + 2ρ στσδ
σ2τ
= 1
σ2τ
(σδ + ρ στ )2 − ρ2. (2)
Now set r := ν2 − 1, then we see that we must have
that r ≥ −ρ2, and we may write
|σδ + ρ στ | = στ
√
r + ρ2.
Hence, we have the following compatible values for σδ{
σδ = στ (
√
r + ρ2 − ρ); r ≥ 0
σδ = στ (±
√
r + ρ2 − ρ); ρ ≤ 0 and − ρ2 ≤ r ≤ 0.
Figure 2: Compatible combinations of r and ρ.
Hatched area has two solutions for σδ.
It is interesting to observe that for negative values
of r (or equivalently, ν < 1) there are two possible
solutions for σδ as visualized in figures (3) and (4).
Since the quantities r = ν2 − 1 and στ are estimable
from data, the main equation (2) implies the following
bound on σδ:
|1− ν| ≤ σδ
στ
≤ 1 + ν.
If we are willing to make assumptions on the values of
ρ, e.g. through domain knowledge, this estimate can
be improved. In case ρ = 0 we have that
σδ = στ
√
ν2 − 1.
From a Bayesian perspective, we may put a distribu-
tion on the values of ρ representing our belief about
the true value of ρ, which in turn yields a probability
distribution on the values of σδ.
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Figure 3: Variability ratio ν against relative treatment
effect heterogeneity σδστ for different levels of assumed
correlation ρ.
Figure 4: Assumed correlation ρ against relative treat-
ment effect heterogeneity σδστ for different levels of
assumed ν.
Figure 5: Compatible region of ρ and σδστ assuming
exemplary 0.87 < ν < 1.1.
4.2 Simulations
In this section we conduct a simulation that illustrates
the compatibility of a variability ratio of 1 and an
average treatment effect of 0 with a TEH of σδ = 1.
We consider the following toy example. Let Y 0, Y 1
be the potential outcome responses under control and
treatment, respectively. We let (Y 0, Y 1 − Y 0) have
a distribution with mean 0 and covariance matrix Σ
given by
Σ =
(
1 −0.5
−0.5 1
)
.
The following python code generates potential out-
comes of this toy model for 10000 units:
import numpy as np
from numpy.random import choice
np.random.seed(1)
rho = -0.5
mu_tau = 0
sigma_tau = 1
mu_delta = 0
sigma_delta = 1
N = 10000
def draw_potential_outcomes(N):
Sigma = np.array(
[
[
sigma_tau ** 2,
rho * sigma_delta * sigma_tau
],
[
rho * sigma_tau * sigma_delta,
sigma_delta ** 2
]
]
)
u = np.random.multivariate_normal(
(mu_tau, mu_delta), Sigma, size=N
)
Y0 = u[:, 0]
Y1 = Y0 + u[:, 1]
return Y0, Y1
The python code below conducts 1000 simulations of
drawing 10000 units from the toy model distribution,
calculating the empirical standard deviation of the
(unobservable) treatment effect, randomly assigning
them into treatment and control groups, and then
calculating the VR effect size statistic.
import pandas as pd
simulations = 1000
def get_simulation_df(simulations, N):
4
df = pd.DataFrame()
for i in range(simulations):
Y0, Y1 = draw_potential_outcomes(N)
# randomize N units into treatment and control
W = np.array([False for _ in range(N)])
N1 = int(N / 2)
W[choice(range(N), N1, replace=False)] = True
Y1_obs = Y1[W]
Y0_obs = Y0[~W]
SD_treatment = Y1_obs.std(ddof=1)
SD_control = Y0_obs.std(ddof=1)
VR = SD_treatment / SD_control
SD_delta = (Y1 - Y0).std()
df = df.append(
{
'VR': VR,
'SD_delta': SD_delta
},
ignore_index=True
)
return df
The python code above was used to generate the
following visualization of the simulations:
Figure 6: Simulated data of 10000 units with ν = 1
and σδ = 0.
5 Discussion and Conclusions
The variability ratio (VR) effect size statistic (defined
in Hedges and Nowell (1995); and proposed in Nak-
agawa et al. (2015)) has been used extensively in
order to study treatment effect heterogeneity (TEH)
in clinical studies. While a VR that is different from 1
is widely acknowledged to implicate a treatment effect
heterogeneity (TEH) the exact relationship between
those two quantities has not been discussed in detail
thus far.
In this note we derived an analytic expression that
connects the VR and the standard deviation of the
treatment effect that includes an unobservable corre-
lation coefficient. This equation implies precise upper
and lower bounds on the the standard deviation of the
treatment effect in terms of the VR and the standard
deviation of the response under placebo.
In particular, we showed that in case that the vari-
ability is equal to 1, the standard deviation of the
treatment effect is at most twice the size of the stan-
dard deviation of the response under placebo. More-
over, if one is willing to make assumptions on the
non-negativity of an unobserved quantity this implies
a constant treatment effect. We illustrated our finding
with visualizations and a simulation.
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